| | 1 | = BioPhysicsX meeting; 27Mar23; 08:00 = |
| | 2 | |
| | 3 | **Present:** AG, CJ, KL, IMcN, PP |
| | 4 | |
| | 5 | == Notes == |
| | 6 | |
| | 7 | 1. //News and updates: // KL, All |
| | 8 | - CIO "Charged Particles for Cancer Therapy": |
| | 9 | - Constitution finalised. Will be submitted this week. |
| | 10 | - Imperial strategy consultation: |
| | 11 | - Qualtrix input: |
| | 12 | - Required by 31Mar23. KL and IMcN will coordinate their input. |
| | 13 | - KL/IMcN considering submitting "one pager" outlining ambitions for LhARA, LhARA initiative, and potential for multidisciplinary institute. |
| | 14 | - Planning round: |
| | 15 | - KL has submitted paragraph of input to Physics planning round submission. IMcN considering submitting "matching" paragraph. |
| | 16 | - CNRS: |
| | 17 | - KL invited as part of "Brady party" to make presentation on LhARA (initiative) at meeting at CNRS HQ in Paris on 03/04Apr23. |
| | 18 | - Possible link between IRL and White City activity. |
| | 19 | |
| | 20 | 2. //BioPhysicsX two-pager: // CJ, All |
| | 21 | - [raw-attachment:The-institute-v0_3.docx Version 0.3] |
| | 22 | - Discussion included the following pointers: |
| | 23 | - Need sentences at the beginning to place the initiative/institute in context; |
| | 24 | - Probably good idea to explain the breadth of the LhARA collaboration; 4-nations UK, international, Institut Curie in particular; |
| | 25 | - Need to emphasis key links with FOM/IC NHS H/c Trust (IMcN), OIRO (AG); |
| | 26 | - Add link to clinical applications: trials, transformation in clinical practice as ambition; |
| | 27 | - Line of sight to clinic; the "why" big picture; |
| | 28 | - Potential for spin-offs; |
| | 29 | - IBA, Hitachi, Mitsubishi, Procure: system-level potential for tie up with medical-equipment provider |
| | 30 | - Instrumentation and computing as incremental/long-term impact plan, and, no-loss theorem; valuable even if LhARA should fail. |
| | 31 | - Biological impact: |
| | 32 | - In particular, unique potential to provide capability to investigate "spatial/temporal impact of beams at very high doses" |
| | 33 | |
| | 34 | - We **agreed** that bullet level inout would be provided to CJ as follows: |
| | 35 | - **IMcN:** Pre-clincal/clinical facing aspects of institute initiative |
| | 36 | - **PP:** I/p on delivering "a new, novel, big, different thing" |
| | 37 | - **AG:** I/p on biology and capability for radiation biology |
| | 38 | |
| | 39 | |
| | 40 | 3. //Actions and next steps: // All |
| | 41 | - Update on two pager, ideally this week. |
| | 42 | |
| | 43 | 4. //DONM// |
| | 44 | - In a month's time. |
| | 45 | |
| | 46 | 5. //AoB// |
| | 47 | |
| | 48 | ---- |
